Compare SENS & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SENS | BNR |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.5M | 233.7M |
| IPO Year | N/A | 2020 |
| Metric | SENS | BNR |
|---|---|---|
| Price | $6.88 | $16.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $25.58 | N/A |
| AVG Volume (30 Days) | ★ 377.0K | 68.7K |
| Earning Date | 11-05-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $29,298,000.00 | ★ $75,749,382.00 |
| Revenue This Year | $59.55 | $136.32 |
| Revenue Next Year | $70.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.94 | 5.56 |
| 52 Week Low | $5.25 | $2.18 |
| 52 Week High | $28.00 | $23.59 |
| Indicator | SENS | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 62.58 | 49.77 |
| Support Level | $6.52 | $15.64 |
| Resistance Level | $6.95 | $18.42 |
| Average True Range (ATR) | 0.39 | 2.44 |
| MACD | 0.02 | -0.61 |
| Stochastic Oscillator | 83.60 | 20.46 |
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.